Skip to main content
Top

23-12-2017 | Renal cell carcinoma | Article

Fatigue among patients with renal cell carcinoma receiving adjuvant sunitinib or sorafenib: patient-reported outcomes of ECOG-ACRIN E2805 trial

Journal: Supportive Care in Cancer

Authors: Fengmin Zhao, David Cella, Judith Manola, Robert S. DiPaola, Lynne I. Wagner, Naomi S. B. Haas

Publisher: Springer Berlin Heidelberg

Abstract

Background

E2805 was a phase III trial to test whether adjuvant sunitinib or sorafenib could improve disease-free survival compared to placebo in patients with renal cell carcinoma. Patient-reported outcomes (PRO), focusing on fatigue, were evaluated as a secondary endpoint.

Patients and methods

A total of 463 patients participated in the PRO study. Fatigue was measured by the FACIT Fatigue scale and PROMIS Fatigue SF1 measure at baseline, week 10, and week 22. The primary endpoint was change in fatigue score from baseline to week 22, measured by the FACIT Fatigue scale. Secondarily, the psychometric properties of PROMIS Fatigue SF1 were assessed in relation to the FACIT Fatigue scale.

Results

Fatigue got significantly worse on all arms after 2 cycles of treatment, and especially so in patients on sunitinib (− 9.6 vs. − 5.6 on sorafenib vs. − 4.7 on placebo). Fatigue remained stable during week 10 and week 22. Overall, the mean score change between baseline and week 22 was − 7.9 (p < 0.001) on sunitinib, − 6.4 (p < 0.001) on sorafenib and − 5.6 (p < 0.001) on placebo arm. The difference in score change was not statistically significant between the two experimental arms and the placebo arm (difference = − 2.34 [p = 0.110] and − 0.87 [p = 0.535] for sunitinib vs. placebo and sorafenib vs. placebo). PROMIS Fatigue SF1 had good internal consistency reliability and construct and criterion validity, and was highly correlated with the FACIT Fatigue scale score.

Conclusions

Fatigue got worse during study period, especially in patients on sunitinib. The PROMIS Fatigue SF1 was highly correlated with FACIT Fatigue and produced similar results.
Literature
1.
Harding G, Cella D, Robinson D Jr, Mahadevia PJ, Clark J, Revicki DA (2007) Symptom burden among patients with renal cell carcinoma (RCC): content for a symptom index. Health Qual Life Outcome 5:34CrossRef
2.
Hutson T, Quinn D (2005) Cytokine therapy: a standard of care for metastatic renal cell carcinoma? Clin Genitourin Cancer 4(3):181–186. https://​doi.​org/​10.​3816/​CGC.​2005.​n.​030 CrossRefPubMed
3.
Malik UR, Makower DF, Wadler S (2001) Interferon-mediated fatigue. Cancer 92(S6):1664–1668. https://​doi.​org/​10.​1002/​1097-0142(20010915)92:​6+<1664:​:​AID-CNCR1494>3.​0.​CO;2-9 CrossRefPubMed
4.
Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, Negrier S, Chevreau C, Solska E, Desai AA, Rolland F, Demkow T, Hutson TE, Gore M, Freeman S, Schwartz B, Shan M, Simantov R, Bukowski RM, TARGET Study Group (2007) Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356(2):125–134. https://​doi.​org/​10.​1056/​NEJMoa060655 CrossRefPubMed
5.
Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, Oudard S, Negrier S, Szczylik C, Kim ST, Chen I, Bycott PW, Baum CM, Figlin RA (2007) Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356(2):115–124. https://​doi.​org/​10.​1056/​NEJMoa065044 CrossRef
6.
Motzer RJ, Hutson TE, Cella D, Reeves J, Hawkins R, Guo J, Nathan P, Staehler M, de Souza P, Merchan JR, Boleti E, Fife K, Jin J, Jones R, Uemura H, de Giorgi U, Harmenberg U, Wang J, Sternberg CN, Deen K, McCann L, Hackshaw MD, Crescenzo R, Pandite LN, Choueiri TK (2013) Pazopanib versus Sunitinib in metastatic renal-cell carcinoma. N Engl J Med 369(8):722–731. https://​doi.​org/​10.​1056/​NEJMoa1303989 CrossRefPubMed
7.
Escudier B, Pluzanska A, Koralewski P, Ravaud A, Bracarda S, Szczylik C, Chevreau C, Filipek M, Melichar B, Bajetta E, Gorbunova V, Bay JO, Bodrogi I, Jagiello-Gruszfeld A, Moore N (2007) Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 370(9605):2103–2111. https://​doi.​org/​10.​1016/​S0140-6736(07)61904-7 CrossRefPubMed
8.
Haas NB, Manola J, Uzzo RG, Flaherty KT, Wood CG, Kane C, Jewett M, Dutcher JP, Atkins MB, Pins M, Wilding G, Cella D, Wagner L, Matin S, Kuzel TM, Sexton WJ, Wong YN, Choueiri TK, Pili R, Puzanov I, Kohli M, Stadler W, Carducci M, Coomes R, DiPaola RS (2016) Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial. Lancet 387(10032):2008–2016. https://​doi.​org/​10.​1016/​S0140-6736(16)00559-6 CrossRef
9.
Ravaud A, Motzer RJ, Pandha HS, George DJ, Pantuck AJ, Patel A, Chang YH, Escudier B, Donskov F, Magheli A, Carteni G, Laguerre B, Tomczak P, Breza J, Gerletti P, Lechuga M, Lin X, Martini JF, Ramaswamy K, Casey M, Staehler M, Patard JJ, S-TRAC Investigators (2016) Adjuvant sunitinib in high-risk renal-cell carcinoma after nephrectomy. N Engl J Med 375(23):2246–2254. https://​doi.​org/​10.​1056/​NEJMoa1611406 CrossRefPubMed
10.
Kollmannsberger C, Soulieres D, Wong R, Scalera A, Gaspo R, Bjarnason G (2007) Sunitinib therapy for metastatic renal cell carcinoma: recommendations for management of side effects. Can Urol Assoc J 1(2 Suppl):S41–S54PubMedPubMedCentral
11.
Chandwani KD, Zhao F, Morrow GR, Deshields TL, Minasian LM, Manola J, Fisch MJ (2017) Lack of patient-clinician concordance in cancer patients: its relation with patient variables. J Pain Symptom Manag 53(6):988–998. https://​doi.​org/​10.​1016/​j.​jpainsymman.​2016.​12.​347 CrossRef
12.
Gravis G, Marino P, Joly F, Oudard S, Priou F, Esterni B, Latorzeff I, Delva R, Krakowski I, Laguerre B, Rolland F, Théodore C, Deplanque G, Ferrero JM, Pouessel D, Mourey L, Beuzeboc P, Zanetta S, Habibian M, Berdah JF, Dauba J, Baciuchka M, Platini C, Linassier C, Labourey JL, Machiels JP, el Kouri C, Ravaud A, Suc E, Eymard JC, Hasbini A, Bousquet G, Soulie M, Fizazi K (2014) Patients’ self-assessment versus investigators’ evaluation in a phase III trial in non-castrate metastatic prostate cancer (GETUG-AFU 15). Eur J Cancer 50(5):953–962. https://​doi.​org/​10.​1016/​j.​ejca.​2013.​11.​034 CrossRefPubMed
13.
Cella D, Lai JS, Chang CH, Peterman A, Slavin M (2002) Fatigue in cancer patients compared with fatigue in the general United States population. Cancer 94(2):528–538. https://​doi.​org/​10.​1002/​cncr.​10245 CrossRef
14.
Lai JS, Crane PK, Cella D (2006). Factor analysis techniques for assessing sufficient unidimensionality of cancer related fatigue. Qual Life Res 15(7):1179–90CrossRef
15.
Lai J-S, Cella D, Yanez B, Stone A (2014) Linking fatigue measures on a common reporting metric. J Pain Symptom Manag 48(4):639–648. https://​doi.​org/​10.​1016/​j.​jpainsymman.​2013.​12.​236 CrossRef
16.
Cella D, Eton DT, Lai JS, Peterman AH, Merkel DE (2002) Combining anchor and distribution-based methods to derive minimal clinically important differences on the Functional Assessment of Cancer Therapy (FACT) anemia and fatigue scales. J Pain Symptom Manag 24(6):547–561. https://​doi.​org/​10.​1016/​S0885-3924(02)00529-8 CrossRef
17.
Yost KJ, Eton DT, Garcia SF, Cella D (2011) Minimally important differences were estimated for six patient-reported outcomes measurement information system-cancer scales in advanced-stage cancer patients. J Clin Epidemiol 64(5):507–516. https://​doi.​org/​10.​1016/​j.​jclinepi.​2010.​11.​018 CrossRefPubMedPubMedCentral
18.
Cella D, Lai JS, Jensen SE, Christodoulou C, Junghaenel DU, Reeve BB, Stone AA (2016) PROMIS fatigue item bank had clinical validity across diverse chronic conditions. J Clin Epidemiol 73:128–134. https://​doi.​org/​10.​1016/​j.​jclinepi.​2015.​08.​037 CrossRef